TCRTAlaunos Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Alaunos Therapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TCRTEsta | $5M#3 | — | 7.5x#6 | 973.0x#5 | -50.0%#5 | 10.8%#6 | -84500.0%#5 | -640.5%#6 | — | — | — | — |
| APRE | $6M#1 | — | 0.2x#1 | — | — | 2.8%#7 | — | -32.8%#2 | — | — | — | — |
| PRPH | $6M#2 | — | — | 1.3x#1 | -35.8%#4 | 72.4%#2 | -415.4%#2 | — | -804.6%#1 | — | -90.0%#2 | — |
| XBIO | $5M#4 | — | 0.8x#4 | 1.6x#3 | 19.0%#3 | 32.3%#5 | -95.2%#1 | -44.1%#3 | -1516.8%#3 | 4#1 | -37.9%#1 | — |
| RVPH | $5M#5 | — | 0.3x#2 | — | — | 33.6%#4 | — | -130.6%#4 | — | — | — | — |
| TRAW | $4M#6 | — | 0.4x#3 | 1.6x#2 | 1134.5%#1 | 105.5%#1 | -640.7%#3 | 79.2%#1 | — | — | — | — |
| ERNA | $3M#7 | 0.0x#1 | 1.1x#5 | 5.9x#4 | 755.9%#2 | 68.4%#3 | -1601.2%#4 | -440.1%#5 | -1016.2%#2 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice